Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Armstrong April W, Gondo George C, Merola Joseph F, Roberts Alyssa M, Pérez-Chada Lourdes M, Balak Deepak M W, Eakin Guy S, Read Charlotte, Le Stephanie T, Gutierrez Yasmin, Bhutani Tina, Blauvelt Andrew, Duffin Kristina Callis, Fakharzadeh Steven, Feldman Steven R, Gelfand Joel M, Gladman Dafna D, Glick Brad, Green Lawrence J, Han George, Hawkes Jason E, Hwang Samuel T, Johnsen Nicole, Kalb Robert E, Kircik Leon, Langley Richard G, Lebwohl Mark G, Lewitt G Michael, Maverakis Emanual, Prussick Ronald, Reddy Soumya M, Rosen Cheryl F, Scher Jose U, Siegel Evan L, Wallace Elizabeth B, Weinberg Jeffrey M, Yamauchi Paul S, Yosipovitch Gil, Liao Wilson, Remission Workgroup of the National Psoriasis Foundation
Аннотация
OBJECTIVE: To establish a consensus-based definition of on-treatment remission for plaque psoriasis through a multistage Delphi initiative.
EVIDENCE REVIEW: The Remission Workgroup from the medical board and scientific advisory board of the National Psoriasis Foundation engaged various stakeholders, both US based and international, to participate in the consensus process. Following a working group meeting to determine the overall consensus approach, a systematic review of remission definitions in the current literature was performed. This review helped to inform the content of consensus materials. The consensus effort involved 2 stages: pre-Delphi interviews and surveys to inform the Delphi questions, followed by a Delphi exercise with physicians to define on-treatment remission for plaque psoriasis. Outcome measures considered included body surface area (BSA), Investigator Global Assessment (IGA), the product of the Physician Global Assessment and body surface area (PGA × BSA), and Psoriasis Area and Severity Index (PASI) score at various cutoff levels and time points.
FINDINGS: The consensus process involved 92 stakeholders, including dermatologists, rheumatologists, researchers, patients, payers, and life sciences professionals. In the pre-Delphi interviews and surveys, patients emphasized that on-treatment remission meant the absence of psoriasis signs and symptoms while recieving therapy. Payers expressed that defining remission is important for long-term treatment coverage. Following the Delphi exercise and discussion with participating physicians specializing in psoriatic disease management, on-treatment remission in plaque psoriasis was defined as patients maintaining a BSA of 0% or IGA of 0 for at least 6 months while on treatment.
CONCLUSIONS AND RELEVANCE: Through a Delphi consensus process, on-treatment remission for plaque psoriasis was defined as patients maintaining a BSA involvement of 0% or IGA of 0 for at least 6 months while on treatment. This clear and standardized benchmark is applicable to both research and practice settings.